Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 4 | EJNMMI Radiopharmacy and Chemistry

Fig. 4

From: Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu

Fig. 4

Tumour growth index (TGI) vs. time (days) in (a) NOD/SCID mice with s.c. PANC-1 xenografts treated with three i.v. (tail vein) injections (10 MBq; 10 μg; ~ 0.07 nmoles) of panitumumab-MCP-111In, panitumumab-DOTA-111In or unlabeled panitumumab (10 μg; ~ 0.07 nmoles) or normal saline separated by 3 weeks or in (b) NRG mice with s.c. PANC-1 xenografts treated with a single i.v. injection (10 MBq; 10 μg; ~ 0.07 nmoles) of panitumumab-DOTA-177Lu or unlabeled panitumumab (10 μg; ~ 0.07 nmoles) or normal saline. The TGI vs. time curves were fitted to an exponential growth model (lines) to estimate tumour doubling times. The body weight index (BWI) is shown in (c) for tumour-bearing NOD/SCID and NRG mice treated with the RICs, unlabeled panitumumab or normal saline

Back to article page